BiotechTube
Modulus Therapeutics

Modulus Therapeutics

Seattle, United States· Est.
modulustherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

Modulus Therapeutics is a private, preclinical-stage biotech developing engineered immune cell therapies for cancer. Founded in 2018 and headquartered in Seattle's prominent biotech hub, the company is positioned in the rapidly evolving field of adoptive cell therapy. As a typical early-stage venture, it is pre-revenue and focused on research and platform development. Its success will hinge on translating its technological concepts into viable clinical candidates and securing substantial partnership or investment capital.

Oncology

Technology Platform

Platform for engineering immune cells (likely T cells or NK cells) with enhanced cancer-targeting capabilities, potentially involving novel receptor designs, gene editing, or tunable control systems.

Funding History

1
Total raised:$3.5M
Seed$3.5M

Opportunities

The large and growing market for cell therapies in oncology, particularly the unmet need in solid tumors, presents a significant opportunity.
Advances in genetic engineering and manufacturing could allow Modulus to develop a differentiated, best-in-class therapy.
The company could also be an attractive partnership or acquisition target for larger pharma firms looking to expand their cell therapy pipelines.

Risk Factors

High scientific risk that the platform may not translate into effective and safe clinical candidates.
Intense competition from numerous well-funded companies in the cell therapy space.
Significant financial risk associated with the high burn rate of preclinical/clinical development and potential challenges in raising sufficient capital.

Competitive Landscape

Modulus operates in a fiercely competitive field with major players like Novartis, Gilead/Kite, Bristol Myers Squibb, and Johnson & Johnson, plus dozens of well-funded biotechs (e.g., Allogene, Caribou Biosciences, Sana Biotechnology). Competition is based on technological differentiation, clinical data, manufacturing capability, and intellectual property. Success requires a clear competitive edge.

More companies in Cell & Gene Therapy →More companies in United States →